Abstract
Rivaroxaban is an oral anticoagulant that is the first available orally active direct Factor Xa inhibitor. In this study, a UV spectrophotometric method was developed for the determination of rivaroxaban content in pharmaceutical formulations and the amount of rivaroxaban released in tablet dissolution studies. The dissolution profile of rivaroxaban was successfully determined with the validated method.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
